About 34,010 results

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
The New England Journal of Medicine; Mandelboim M, .

Mar 16th, 2022 - In this open-label, nonrandomized clinical study, we assessed the immunogenicity and safety of a fourth dose of either BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) administered 4 months after the third dose in a series of three BNT162b2 doses (ClinicalTrials.gov numbers, NCT05231005. opens in new tab and NCT05230953. opens in new tab; the protocol is available w...

Antibody Response to a Fourth Messenger RNA COVID-19...
Annals of Internal Medicine; Caillard S, Thaunat O et. al.

Jan 11th, 2022 - Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series.|2022|Caillard S,Thaunat O,Benotmane I,Masset C,Blancho G,|prevention & control,genetics,

Herpes Zoster Following a Nucleoside-Modified Messenger RNA COVID-...
Cutis Dezoteux F, Massip É et. al.

Feb 19th, 2022 - Herpes zoster (HZ) was suspected as a predictive cutaneous manifestation of COVID-19, with a debated prognostic significance. We report a series of 5 cases of HZ occurring after vaccination with a nucleoside-modified messenger RNA (mRNA) COVID-19 vaccine (Comirnaty, Pfizer-BioNTech). These new cases do not prove causality between COVID...

Fourth dose of COVID vaccine offers only slight boost against Omicron infection
Nature Mallapaty S.

Feb 23rd, 2022 - A fourth dose of a COVID-19 vaccine restores antibodies to levels observed after the third dose but provides only a modest boost in protection against infection, according to a small trial carried out in Israel1.

Fourth dose of COVID vaccine offers only slight boost again...
Nature Mallapaty S

Feb 25th, 2022 - Fourth dose of COVID vaccine offers only slight boost against Omicron infection.|2022|Mallapaty S,|

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in...
The New England Journal of Medicine; Mevorach D, Anis E et. al.

Oct 7th, 2021 - Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) by May 31, 2021. After early reports of myocarditis during adverse events monitoring, the Israeli Ministry of Health initiated active surveillance. We retrospectively re...

Fourth dose of COVID-19 vaccines in Israel.
The Lancet. Respiratory Medicine; Burki TK

Jan 15th, 2022 - Fourth dose of COVID-19 vaccines in Israel.|2022|Burki TK,|

Myocarditis Following mRNA COVID-19 Vaccine.
Pediatric Emergency Care; Visclosky T, Theyyunni N et. al.

Nov 4th, 2021 - A growing number of adolescents are being diagnosed with acute myocarditis following mRNA COVID-19 vaccinations. This case describes an adolescent who presented to the emergency department with chest pain and tachycardia following the Pfizer-BioNTech COVID-19 vaccination. Point-of-care ultrasound was performed prior to the return of laboratory studies and reve...

Fourth COVID-19 Vaccine Dose Increases Low Antibodies.
JAMA Abbasi J

Feb 9th, 2022 - Fourth COVID-19 Vaccine Dose Increases Low Antibodies.|2022|Abbasi J,|blood,immunology,blood,immunology,

Fourth COVID-19 Vaccine Dose Boosts Antibodies Fivefold in Israeli Study, PM Says

Jan 5th, 2022 - JERUSALEM (Reuters) - A fourth dose of COVID-19 vaccine boosts antibodies five-fold a week after the shot is administered, Israeli Prime Minister Naftali Bennett said on Tuesday, citing preliminary findings of an Israeli study. "A week into the fourth dose, we know to a higher degree of certainty that the fourth dose is safe," Benne...

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine...
The New England Journal of Medicine; Magen O, Waxman JG et. al.

Apr 14th, 2022 - With large waves of infection driven by the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alongside evidence of waning immunity after the booster dose of coronavirus disease 2019 (Covid-19) vaccine, several countries have begun giving at-risk persons a fourth vaccine dose. To evaluate t...

Effectiveness of a Fourth Dose of COVID-19 mRNA V...
Annals of Internal Medicine; Tan CY, Chiew CJ et. al.

Sep 13th, 2022 - Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron Variant Among Elderly People in Singapore.|2022|Tan CY,Chiew CJ,Lee VJ,Ong B,Lye DC,|

Preserved recognition of Omicron spike following COVID-19 messe...
American Journal of Obstetrics and Gynecology; Bartsch YC, Atyeo C et. al.

Apr 18th, 2022 - SARS-CoV-2 infection is associated with enhanced disease severity in pregnant women. Despite the potential of COVID-19 vaccines to reduce severe disease, vaccine uptake remained relatively low among pregnant women. Just as coordinated messaging from the Centers for Disease Control and Prevention and leading obstetrics organizations began to increase vaccine co...

Effectiveness of a fourth dose of covid-19 mRNA v...
BMJ (Clinical Research Ed.); Grewal R, Kitchen SA et. al.

Jul 7th, 2022 - To estimate the marginal effectiveness of a fourth versus third dose and the vaccine effectiveness of mRNA covid-19 vaccines BNT162b2 and mRNA-1273 against any infection, symptomatic infection, and severe outcomes (hospital admission or death) related to the omicron variant. Test negative design. Long term care facilities in Ontario...

Hospitalized patients with severe COVID-19 during the Omicron wave...
Clinical Infectious Diseases : an Official Publication Of... Brosh-Nissimov T, Hussein K et. al.

Jun 21st, 2022 - Waning vaccine-immunity and an increased incidence of COVID-19 during the Omicron outbreak led the Israeli Ministry of Health to recommend a fourth dose of BNT162b2 for high-risk individuals. This study assessed the effect of that dose for hospitalized patients with severe/critical, breakthrough COVID-19. In this multi-center retros...

Nucleoside-modified messenger RNA COVID-19 vaccine p...
Journal of Medical Virology; Roncati L, Corsi L

Mar 7th, 2021 - On March 11, 2020, the World Health Organization declared coronavirus disease 2019 (COVID-19) a pandemic; from that date, the vaccine race has begun, and many technology platforms to develop a specific and effective COVID-19 vaccine have been launched in several clinical trials (protein subunit, RNA-based, DNA-based, replicating viral vect...

Herpes Zoster Following a Nucleoside-Modified Messenger RNA COVID-19 Vaccine
Frédéric Dezoteux, MD, Édouard Massip, MBBS et. al.

Jan 5th, 2022 - Since the end of 2019, COVID-19 infection caused by SARS-CoV-2 has spread in a worldwide pandemic. The first cutaneous manifestations possibly linked to COVID-19 were reported in spring 2020.

Evaluating COVID-19 Vaccine-Related Messenger RNA in...
JAMA Pediatrics; Egwang TG

Oct 19th, 2021 - Evaluating COVID-19 Vaccine-Related Messenger RNA in Breast Milk.|2021|Egwang TG,|

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
The New England Journal of Medicine; Polack FP, Thomas SJ et. al.

Dec 11th, 2020 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years...

Safety and Efficacy of CVnCoV, a 2-Dose Unmodified mRNA Vaccine for COVID-19
Infectious Disease Advisor

Dec 13th, 2021 - The CVnCoV mRNA COVID-19 vaccine was found to be safe and efficacious for protection against SARS-CoV-2 infection, regardless of disease severity. These findings were published in The Lancet Infectious Diseases. In an ongoing, randomized, observer-blinded, placebo-controlled trial conducted at 47 centers in Europe and Latin America, researchers sought to assess the s...